Literature DB >> 7871058

Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

E M Goodall1, P J Cowen, M Franklin, T Silverstone.   

Abstract

This study investigated the role of the 5-HT2/1C receptor antagonist ritanserin on d-fenfluramine (d-FF) induced changes in food intake, prolactin (PRL) secretion and oral temperature in 12 healthy male volunteers. The study was double blind and placebo controlled. Food intake was measured using an automated food dispenser. d-FF (30 mg) significantly reduced fat intake. While ritanserin (5 mg) had no effect when given alone it abolished the d-FF induced reduction in fat intake. In addition, ritanserin abolished the d-FF induced rise in PRL and oral temperature. The results suggest that 5-HT2 or 5-HT1C receptors mediate the effects of d-fenfluramine on appetite, prolactin secretion and temperature in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7871058     DOI: 10.1007/bf02244895

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

Review 1.  Molecular pharmacology and biology of 5-HT1C receptors.

Authors:  D Hoyer
Journal:  Trends Pharmacol Sci       Date:  1988-03       Impact factor: 14.819

2.  The effect of cyproheptadine on hunger, calorie intake and body weight in man.

Authors:  T Silverstone; D Schuyler
Journal:  Psychopharmacologia       Date:  1975

3.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

4.  A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients.

Authors:  M Muijen; D Roy; T Silverstone; A Mehmet; M Christie
Journal:  Acta Psychiatr Scand       Date:  1988-09       Impact factor: 6.392

5.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

6.  A comparison of the effects of d- and l-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects.

Authors:  E Goodall; S Feeney; J McGuirk; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine.

Authors:  A Quattrone; G Tedeschi; U Aguglia; F Scopacasa; G F Direnzo; L Annunziato
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

8.  The measurement of d-fenfluramine and its metabolite, d-norfenfluramine in plasma and urine with an application of the method to pharmacokinetic studies.

Authors:  R P Richards; B H Gordon; R M Ings; D B Campbell; L J King
Journal:  Xenobiotica       Date:  1989-05       Impact factor: 1.908

9.  The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects.

Authors:  J McGuirk; T Silverstone
Journal:  Int J Obes       Date:  1990-04

10.  Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion.

Authors:  G Di Renzo; S Amoroso; M Taglialatela; L Canzoniero; V Basile; A Fatatis; L Annunziato
Journal:  Eur J Pharmacol       Date:  1989-03-21       Impact factor: 4.432

View more
  17 in total

1.  Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects.

Authors:  Sophie M Banas; Stéphane Doly; Katia Boutourlinsky; Silvina L Diaz; Arnauld Belmer; Jacques Callebert; Corinne Collet; Jean-Marie Launay; Luc Maroteaux
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 2.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.

Authors:  S P Vickers; K R Benwell; R H Porter; M J Bickerdike; G A Kennett; C T Dourish
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype.

Authors:  S P Vickers; P G Clifton; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

6.  Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.

Authors:  Sonia Ancoli-Israel; Kimberly E Vanover; David M Weiner; Robert E Davis; Daniel P van Kammen
Journal:  Sleep Med       Date:  2011-01-21       Impact factor: 3.492

7.  Analysis of T102C 5HT2A polymorphism in Brazilian psychiatric inpatients: relationship with suicidal behavior.

Authors:  H Correa; L De Marco; W Boson; M M Viana; V F S Lima; A C Campi-Azevedo; J C M Noronha; C Guatimosim; Marco A Romano-Silva
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

8.  Aggression, suicidality, and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects.

Authors:  Emil F Coccaro; Royce Lee; Richard J Kavoussi
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 10.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.